Rehabtronics to Join PressureSmart Consortium for Advancing Pressure Injury Prevention Using Artificial Intelligence (AI)

Rehabtronics, a leader in advancing neurostimulation technology, is joining the PressureSmart Consortium in collaboration with six leading partners — Medtronic, Swift Medical, Thrive Health, Amii (Alberta Machine Intelligence Institute), Excelar, and Providence Health Care Ventures. This innovative project, co-funded by DIGITAL, Canada’s Global Innovation Cluster for digital technologies, aims to revolutionize the prevention, early detection, and management of pressure injuries (PIs).

Pressure injuries, which affect 26% of patients in Canadian healthcare settings, significantly diminish the patient’s quality of life and lead to costly, extended hospital stays. Rehabtronics’ proprietary technology Prelivia is designed to protect patients from pressure injuries by stimulating blood circulation, thereby increasing tissue oxygenation, and decreasing pressure induced tissue damage.

“We are pleased to collaborate with leading experts in advancing our mission to transform pressure injury care’ states Rahul Samant, CEO of Rehabtronics. “The integration of our Prelivia technology into the PressureSmart platform provides a cost-effective intervention for patients at risk or showing early signs of pressure injuries. Partnering with other technology leaders also allows us to leverage our combined strengths and deliver a scalable, comprehensive solution for managing pressure injuries.”

In addition to its Prelivia early intervention technology, Rehabtronics will develop an AI/ML (Artificial Intelligence/Machine Learning) model for the prediction of new and progressing hospital-acquired pressure injuries. This will enable nursing resources to be focused on the patients most in need.

“AI will revolutionize global health care systems by providing greater access and better outcomes for Canadians and for people around the world,” says Sue Paish, CEO of DIGITAL. “DIGITAL is proud to co-invest alongside Canadian innovators to support partnerships such as the PressureSmart project team to amplify Canadian industry expertise in building relevant AI solutions that advance human health while building global commercial pathways for Canadian companies.”

With a total budget of over 22 million, the PressureSmart project will enable clinicians and caregivers to track patient positioning, identify high-risk areas for PIs, and facilitate early intervention. This cohesive solution aims to enhance patient outcomes and quality of life, reduce clinical staff burden, and provide a scalable approach to address PI (Pressure Injuries) care.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”